



BLA 761355/S-006

## SUPPLEMENT APPROVAL

Regeneron Pharmaceuticals, Inc.  
Attention: Donato Forlenza, PharmD, MBA  
Senior Director, Regulatory Affairs  
777 Old Saw Mill River Road  
Tarrytown, NY 10591

Dear Dr. Forlenza:

Please refer to your supplemental biologics license application (sBLA), dated and received July 15, 2024, and your amendments, submitted under section 351(a) of the Public Health Service Act for Eylea HD (afibercept) injection. This Prior Approval supplemental biologics application provides for the addition of “scleritis” in the ADVERSE REACTIONS, *Postmarketing Experience* subsection of the Prescribing Information.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,<sup>1</sup> that is identical to the enclosed labeling (text for the Prescribing Information,) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.

If you have any questions, please contact Michael Puglisi, Regulatory Project Manager at [michael.puglisi@fda.hhs.gov](mailto:michael.puglisi@fda.hhs.gov) or call (301) 796-0791.

Sincerely,

*{See appended electronic signature page}*

William Boyd, MD  
Deputy Director  
Division of Ophthalmology  
Office of Specialty Medicine  
Office of New Drugs  
Center for Drug Evaluation and Research

### ENCLOSURE:

- Content of Labeling
  - Prescribing Information

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

WILLIAM M BOYD  
10/10/2024 01:35:24 PM